Jean A Klastersky1. 1. Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
Abstract
PURPOSE OF REVIEW: There is currently an explosion in the number of so-called targeted therapies. As new indications for these agents multiply, there is also an increase of new and less new side-effects. RECENT FINDINGS: Given this rapidly evolving field, any literature on that topic is rapidly obsolete and needs re-evaluation. SUMMARY: Targeted therapies are associated with a wide spectrum of adverse events, which cannot always be easily separated from the complications linked to cancer, its therapy, and comorbidities. A high awareness of these events might improve the patient's quality of life and contribute to the recognition of new syndromes.
PURPOSE OF REVIEW: There is currently an explosion in the number of so-called targeted therapies. As new indications for these agents multiply, there is also an increase of new and less new side-effects. RECENT FINDINGS: Given this rapidly evolving field, any literature on that topic is rapidly obsolete and needs re-evaluation. SUMMARY: Targeted therapies are associated with a wide spectrum of adverse events, which cannot always be easily separated from the complications linked to cancer, its therapy, and comorbidities. A high awareness of these events might improve the patient's quality of life and contribute to the recognition of new syndromes.
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959